COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRAN

被引：0
|
作者：
Davari, M. [1 ]
Khorasani, E. [1 ]
Shojaei, Savari R. [1 ]
Sari, Akbari A. [2 ]
Saiyarsarai, P. [3 ]
机构：
[1] Univ Tehran Med Sci, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran
[3] Univ Tehran Med Sci, Dept Pharmacoecon & Pharmaceut Management, Fac Pharm, Tehran, Iran
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.774
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB69
引用
收藏
页码：S129 / S130
页数：3
相关论文
共 50 条
  • [1] PROactive 06:: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK
    Valentine, W. J.
    Bottomley, J. M.
    Palmer, A. J.
    Braendle, M.
    Foos, V.
    Williams, R.
    Dormandy, J. A.
    Yates, J.
    Tan, M. H.
    Massi-Benedetti, M.
    DIABETIC MEDICINE, 2007, 24 (09) : 982 - 1002
  • [2] Cost-effectiveness of pioglitazone in type 2 diabetes in Switzerland based on the PROactive study
    Brandle, M.
    Valentine, W.
    Goodall, G.
    Dumont, N.
    Pang, F.
    Benedetti, M. Massi
    DIABETOLOGIA, 2007, 50 : S428 - S428
  • [3] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    VALUE IN HEALTH, 2019, 22 : S576 - S576
  • [4] The cost-effectiveness of insulin glulisine in type 2 diabetes in Poland
    Walczak, J.
    Dardzinski, W.
    Kusy, M.
    Lis, J.
    Nogas, G.
    VALUE IN HEALTH, 2008, 11 (03) : A226 - A226
  • [5] Cost-effectiveness of adding rimonabant to the treatment regimen of overweight and obese patients with diabetes
    Getsios, Denis
    Caro, J. J.
    Moeller, Jorgen
    McEwan, Phil
    Danel, Aurelie
    Ishak, Khajak
    DIABETES, 2007, 56 : A310 - A310
  • [6] Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran
    Amirsadri, Mohammadreza
    Torkpour, Elahe
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2023, 18 (02) : 210 - 218
  • [7] COST-EFFECTIVENESS OF ADDING TWICE-DAILY EXENATIDE TO BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES IN SCOTLAND
    Varol, N.
    Wilson, B. P.
    Norrbacka, K.
    Valentine, W. J.
    Pollock, R. F.
    VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [8] The cost-effectiveness of pioglitazone in combination with metformin in the treatment of type 2 diabetes mellitus in Scotland
    Stynes, G
    Tilden, D
    Swift, M
    Cockle, S
    Haycox, A
    Aristides, M
    VALUE IN HEALTH, 2004, 7 (06) : 737 - 738
  • [9] Cost-Effectiveness of Pioglitazone in Patients with Type 2 Diabetes and a History of Macrovascular Disease in Germany
    Bierwirth, R.
    Liebl, A.
    Gschwend, M. H.
    DIABETOLOGIE UND STOFFWECHSEL, 2010, 5 (01) : 32 - 39
  • [10] An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes
    Home, Philip
    Baik, Sei Hyun
    Gonzalez Galvez, Guillermo
    Malek, Rachid
    Nikolajsen, Annie
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 230 - 240
12345